These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 15318391)
1. Remarks of the acting FDA commissioner: FDLI's 47th annual conference. Crawford LM Food Drug Law J; 2004; 59(2):201-8. PubMed ID: 15318391 [No Abstract] [Full Text] [Related]
2. Remarks of the Acting FDA Commissioner: FDLI's 48th annual conference. Crawford LM Food Drug Law J; 2005; 60(2):99-102. PubMed ID: 16097087 [No Abstract] [Full Text] [Related]
3. Remarks at FDLI's 46th annual educational conference. Waxman HA Food Drug Law J; 2003; 58(2):205-9. PubMed ID: 12866553 [No Abstract] [Full Text] [Related]
4. Remarks of the Commissioner of Food and Drugs. McClellan MB Food Drug Law J; 2003; 58(2):191-204. PubMed ID: 12866552 [No Abstract] [Full Text] [Related]
5. FDA embraces risk-management approach. Fox JL Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383 [No Abstract] [Full Text] [Related]
6. ORA's role at FDA headquarters and in the field for product recalls. Whetstone SN Food Drug Law J; 1998; 53(3):513-6. PubMed ID: 10346723 [No Abstract] [Full Text] [Related]
7. Remarks by the Commissioner. FDA. Kessler DA J Parenter Sci Technol; 1991; 45(3):118-21. PubMed ID: 1886036 [No Abstract] [Full Text] [Related]
8. Remarks delivered at the Food and Drug Law Institute's 48th Annual Conference. Enzi MB Food Drug Law J; 2005; 60(2):103-6. PubMed ID: 16097090 [No Abstract] [Full Text] [Related]
9. The FDA and the fight against terrorism. Meadows M FDA Consum; 2004; 38(1):20-7. PubMed ID: 15032200 [No Abstract] [Full Text] [Related]
10. Medical device safety: FDA's postmarket transformation initiative. Schultz D Food Drug Law J; 2007; 62(3):593-6. PubMed ID: 17915401 [No Abstract] [Full Text] [Related]
11. An interview with FDA commissioner Hayes. Small WE Am Pharm; 1981 Oct; NS21(10):27-36. PubMed ID: 6803557 [No Abstract] [Full Text] [Related]
12. FDA: the regulatory process. Slutsky AS Respir Care; 1995 Sep; 40(9):952-6. PubMed ID: 10152239 [No Abstract] [Full Text] [Related]
13. Remarks of the Commissioner of Food and Drugs. Henney JE Food Drug Law J; 2000; 55(1):1-4. PubMed ID: 12269355 [No Abstract] [Full Text] [Related]
14. Mission: promoting, protecting the public health. FDA Commissioner Mark B. McClellan. Interview by Ray Formanek Jr. McClellan MB FDA Consum; 2003; 37(2):12-7. PubMed ID: 12715764 [No Abstract] [Full Text] [Related]
15. A voluntary disclosure program for FDA--the time has come. Fleder JR Food Drug Law J; 1999; 54(3):389-99. PubMed ID: 11797705 [No Abstract] [Full Text] [Related]
16. FDA reform: the need for a sound science-based approach. Cady J Food Drug Law J; 1996; 51(3):407-12. PubMed ID: 11797717 [No Abstract] [Full Text] [Related]
17. Tort law deference to FDA regulation of medical devices. Green MD; Schultz WB Georgetown Law J; 2000 Jul; 88(7):2119-45. PubMed ID: 11503660 [No Abstract] [Full Text] [Related]
18. FDA law enforcement: critical to product safety. Rados C FDA Consum; 2006; 40(1):21-7. PubMed ID: 16528823 [No Abstract] [Full Text] [Related]
19. Dirty dancing--the FDA stumbles with the Chevron two-step: a response to professor Noah. Lawson G Cornell Law Rev; 2008 Jul; 93(5):927-38. PubMed ID: 18618964 [No Abstract] [Full Text] [Related]
20. Supreme Court opens door to personal injury suits against FDA. Smith GR Healthspan; 1988; 5(7):12-4. PubMed ID: 10288659 [No Abstract] [Full Text] [Related] [Next] [New Search]